Events

Adamed to acquire Sanofi manufacturing plant in Spain

22 January 2026

Adamed Pharma has signed a preliminary agreement with Sanofi to acquire its manufacturing plant in Riells i Viabrea, Spain. The acquisition marks another step in the Polish company’s international growth. The transaction is intended to increase production capacity, diversify manufacturing locations, strengthen supply-chain resilience and improve medicine security in Europe. 

Transaction timetable and terms 

The formal closing of the transaction is planned for the second quarter of 2026. Until then, production will continue without disruption, and the acquisition process will be carried out gradually. 

After the transition period, Adamed will assume operational management of the plant. The company plans to maintain the current level of employment and existing working conditions. 

“We want to build on what is already there: the people, their knowledge and their experience. This is a solid plant with a future ahead of it. It is a long-term project in which we intend to invest so that it can play an important role in the years to come,” said Małgorzata Adamkiewicz, MD, PhD, President of the Supervisory Board and co-owner of Adamed Pharma. 

The future development of the Riells plant 

The Riells plant has operated for more than 50 years and specialises in manufacturing tablets and capsules. It employs more than 200 people and produces approximately 75 million packs of medicines annually. Its products are supplied to 77 countries worldwide, primarily for export. 

“The Riells plant plays an important role in delivering medicines to patients around the world. We are committed to the long-term stability and development of manufacturing facilities. We are confident that under Adamed’s leadership, the plant will continue to meet the highest quality and safety standards,” said Marzia Bove, Head of Manufacturing and Supply for Sanofi’s General Medicines cluster. 

The facility will become one of the key sites in Adamed’s international manufacturing network, focused on high-volume medicines supplied primarily to European markets. The company will invest in modernising production, infrastructure and logistics and adapting the site to current and new products. 

“For large international manufacturing companies, reducing dependence on a single production location is standard practice. Diversification gives us greater flexibility and operational reliability. Spain is a strategic location for us, close to the Latin American markets where we want to strengthen our presence,” said Paweł Roszczyk, Managing Director of Adamed Pharma.

Sanofi’s decision 

Sanofi’s decision to sell the Riells plant reflects the Group’s strategy to become a global leader in immunology and to adapt its global industrial network to the future needs of medicines under development. 

Under the agreement, in addition to introducing Adamed products, the Riells plant will continue to manufacture Sanofi medicines for several years. This will ensure full continuity of supply and no change for patients. Ownership and commercial distribution of the products will remain with Sanofi. 

Spain and Poland at the heart of Adamed’s growth 

Adamed has operated in Spain through Adamed Laboratorios since 2009. Spain is now the company’s second-largest European market by revenue and offers a stable growth outlook. 

At the same time, Adamed continues to invest in Poland, where it operates two manufacturing facilities in Pabianice and Ksawerów. The company is expanding its Manufacturing and Logistics Centre in Pabianice and plans to invest approximately PLN 300 million by 2030, including in a new inhaled-medicines plant. Over the last five years, Adamed has increased medicine production by 75%, from two billion to 3.5 billion tablets annually. Following the acquisition of the Riells plant, the company plans to double production volume to seven billion tablets annually by 2029. 

The international strategy of a Polish company 

The Riells plant will be the second overseas factory in Adamed’s international manufacturing network. The company has owned a factory in Vietnam since 2017. Adamed medicines reach patients in more than 80 countries across six continents.